

# Francesco Patti

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5708951/publications.pdf](https://exaly.com/author-pdf/5708951/publications.pdf)

Version: 2024-02-01

331  
papers

12,600  
citations

33972

52  
h-index

43165

92  
g-index

363  
all docs

363  
docs citations

363  
times ranked

12606  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. <i>Journal of Medical Economics</i> , 2024, 27, 109-125.	2.2	0
2	Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2024, 95, 620-625.	6.0	0
3	Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. <i>Therapeutic Advances in Neurological Disorders</i> , 2024, 17, .	3.8	0
4	Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis. <i>Neurology</i> , 2024, 102, .	1.1	0
5	Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2024, 95, 767-774.	6.0	1
6	Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study. <i>Neurotherapeutics</i> , 2024, , e00363.	4.7	0
7	Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2024, 10, .	1.1	0
8	Correlation between patient-reported manual ability and three objective measures of upper limb function in people with multiple sclerosis. <i>European Journal of Neurology</i> , 2023, 30, 172-178.	3.6	5
9	Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry. <i>Multiple Sclerosis Journal</i> , 2023, 29, 221-235.	3.3	15
10	Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 70, 104474.	2.1	0
11	Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2023, 30, 1014-1024.	3.6	1
12	Pregnancy planning and management for women with multiple sclerosis: what has changed over the last 15 years? An Italian single-center experience. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 70, 104526.	2.1	3
13	Comparative effectiveness in multiple sclerosis: A methodological comparison. <i>Multiple Sclerosis Journal</i> , 2023, 29, 326-332.	3.3	3
14	Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2023, 29, 875-883.	3.3	7
15	Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression. <i>Journal of Clinical Medicine</i> , 2023, 12, 2215.	2.5	3
16	Sars-CoV2 infection in pregnant women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2023, 29, 1090-1098.	3.3	1
17	Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY). <i>Neurotherapeutics</i> , 2023, 20, 1696-1706.	4.7	7
18	A <i>post hoc</i> evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, .	3.8	0

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid neurofilament light chains predicts early disease-activity in Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 80, 105131.	2.1	1
20	Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. <i>Multiple Sclerosis Journal</i> , 2023, 29, 1808-1818.	3.3	4
21	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. <i>Journal of Neurology</i> , 2022, 269, 933-944.	3.8	12
22	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2022, 28, 472-479.	3.3	14
23	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. <i>Journal of Neurology</i> , 2022, 269, 1463-1469.	3.8	5
24	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	3.3	38
25	Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. <i>Neurological Sciences</i> , 2022, 43, 1903-1910.	2.0	10
26	Rituximab for the treatment of multiple sclerosis: a review. <i>Journal of Neurology</i> , 2022, 269, 159-183.	3.8	105
27	Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103361.	2.1	17
28	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103385.	2.1	11
29	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 535-542.	3.6	8
30	Spinal needle and post-dural puncture headache. <i>Neurological Sciences</i> , 2022, 43, 1467-1468.	2.0	1
31	Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. <i>Current Neuropharmacology</i> , 2022, 20, 1978-1987.	3.0	5
32	COVID-19 Severity in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.8	60
33	Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103489.	2.1	2
34	Reliability of televisits for patients with mild relapsing/remitting multiple sclerosis in the COVID-19 era. <i>Neurological Sciences</i> , 2022, 43, 2253-2261.	2.0	4
35	Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.8	31
36	Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 483-495.	5.8	8

#	ARTICLE	IF	CITATIONS
37	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. <i>Journal of Clinical Medicine</i> , 2022, 11, 942.	2.5	8
38	Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 819136.	4.9	10
39	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2137-2141.	3.3	4
40	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. <i>Brain</i> , 2022, 145, 2796-2805.	8.0	61
41	Paediatric Multiple Sclerosis: A Scoping Review of Patients' and Parents' Perspectives. <i>Children</i> , 2022, 9, 11.	1.5	4
42	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. <i>Neurology</i> , 2022, 98, e1626-e1636.	1.1	8
43	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. <i>Lancet Neurology</i> , 2022, 21, 608-619.	10.4	58
44	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. <i>Value in Health</i> , 2022, 25, 1489-1498.	0.3	3
45	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 6069.	2.7	2
46	A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described "spasticity-plus syndrome". <i>European Journal of Neurology</i> , 2022, 29, 2744-2753.	3.6	13
47	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103909.	2.1	4
48	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> , 2022, 269, 5382-5394.	3.8	50
49	Patients with multiple sclerosis: a burden and cost of illness study. <i>Journal of Neurology</i> , 2022, 269, 5127-5135.	3.8	17
50	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2106-2111.	3.3	34
51	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104025.	2.1	23
52	Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2243-2252.	3.3	6
53	Signs and symptoms of COVID-19 in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 3728-3736.	3.6	8
54	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , 2021, 96, e214-e227.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. <i>Neurological Sciences</i> , 2021, 42, 2837-2845.	2.0	12
56	Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1458-1463.	3.3	9
57	An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. <i>Journal of Neurology</i> , 2021, 268, 3249-3268.	3.8	46
58	The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. <i>Dysphagia</i> , 2021, 36, 192-197.	2.1	10
59	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021, 28, 567-578.	3.6	6
60	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	3.3	20
61	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021, 28, 149-160.	1.5	21
62	Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232098312.	2.6	17
63	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110195.	3.8	60
64	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.3	4
65	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.8	389
66	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	4.7	9
67	Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 $\text{IgG}$ -Positive NMOSD. <i>Annals of Neurology</i> , 2021, 89, 1088-1098.	5.8	62
68	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. <i>Journal of Neurology</i> , 2021, 268, 1540-1543.	3.8	4
69	Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102756.	2.1	4
70	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	45
71	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.	4.7	29
72	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2284-2287.	3.3	9

#	ARTICLE	IF	CITATIONS
73	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 414.	9.3	103
74	Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5588.	2.7	5
75	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.	9.3	31
76	First-line therapies in late-onset multiple sclerosis: An Italian registry study. <i>European Journal of Neurology</i> , 2021, 28, 4117-4123.	3.6	21
77	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	94
78	Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. <i>BMJ Neurology Open</i> , 2021, , .	2.0	0
79	Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. <i>BMC Neurology</i> , 2021, 21, 324.	1.8	12
80	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <sc>REGAIN</sc> and its extension study. <i>Muscle and Nerve</i> , 2021, 64, 662-669.	2.3	13
81	Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103160.	2.1	3
82	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.6	12
83	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. <i>Neurology and Therapy</i> , 2021, 10, 627-649.	3.5	10
84	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. <i>BMC Neurology</i> , 2021, 21, 462.	1.8	5
85	Lack of association between <i>Toxocara canis</i> and multiple sclerosis: A population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 258-259.	3.3	3
86	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020, 42, 3780-3792.	1.8	21
87	Lack of evidence for <i>Toxocara</i> infection in Italian myelitis patients. <i>Neurological Sciences</i> , 2020, 41, 239-241.	2.0	2
88	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 445-453.	3.6	21
89	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. <i>Health and Social Care in the Community</i> , 2020, 28, 236-246.	1.7	19
90	An "all-wheel drive" proposal to accelerate clinical research in common and rare neurological diseases. <i>Neurological Sciences</i> , 2020, 41, 789-793.	2.0	0

#	ARTICLE	IF	CITATIONS
91	Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. <i>Neurological Sciences</i> , 2020, 41, 1075-1079.	2.0	14
92	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. <i>Environmental Research</i> , 2020, 182, 109022.	7.7	11
93	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	2.1	32
94	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1297-1303.	6.0	30
95	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102492.	2.1	22
96	Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102561.	2.1	27
97	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 914-920.	6.0	5
98	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. <i>Frontiers in Neurology</i> , 2020, 11, 756.	2.5	6
99	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	8.0	29
100	Comparing 16 Different Dual-Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitive-Motor Interference. <i>Frontiers in Neurology</i> , 2020, 11, 918.	2.5	17
101	Reply to Comment on "Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study". <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6492.	2.7	1
102	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020, 143, 3013-3024.	8.0	58
103	Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. <i>International Journal of Rehabilitation Research</i> , 2020, 43, 199-205.	1.4	6
104	<i>Toxoplasma gondii</i> and multiple sclerosis: a population-based case-control study. <i>Scientific Reports</i> , 2020, 10, 18855.	3.4	15
105	&lt;p&gt;BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT&lt;sup&gt;A&lt;/sup&gt;. Patient Preference and Adherence, 2020, Volume 14, 771-779.	1.9	5
106	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1449-1454.	1.9	11
107	EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. <i>Journal of Palliative Medicine</i> , 2020, 23, 1426-1443.	1.2	15
108	EAN guideline on palliative care of people with severe, progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 1510-1529.	3.6	25

#	ARTICLE	IF	CITATIONS
109	Palliative care in multiple sclerosis: European guideline. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1009-1011.	3.3	2
110	Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double-blind, placebo-controlled, crossover study. <i>European Journal of Neurology</i> , 2020, 27, 2209-2216.	3.6	13
111	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. <i>Journal of Neurology</i> , 2020, 267, 3008-3020.	3.8	19
112	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. <i>Frontiers in Neurology</i> , 2020, 11, 105.	2.5	8
113	Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. <i>Journal of Neurology</i> , 2020, 267, 1812-1823.	3.8	5
114	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2020, 40, 319-326.	2.2	6
115	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. <i>Environmental Research</i> , 2020, 188, 109820.	7.7	17
116	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642092268.	3.8	31
117	Box and block test, hand grip strength and nine-hole peg test: correlations between three upper limb objective measures in multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 2523-2530.	3.6	21
118	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). <i>Neurological Sciences</i> , 2020, 41, 1881-1889.	2.0	0
119	Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2020, 41, 1539-1546.	2.0	10
120	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 771-782.	2.8	6
121	An update on the pharmacological management of pain in patients with multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2249-2263.	1.9	16
122	Listening to the neurological teams for multiple sclerosis: the SMART project. <i>Neurological Sciences</i> , 2020, 41, 2231-2240.	2.0	6
123	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. <i>CNS Drugs</i> , 2020, 34, 535-543.	6.2	6
124	Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2882.	2.7	49
125	Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. <i>Neurological Sciences</i> , 2020, 41, 2905-2913.	2.0	15
126	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102124.	2.1	21



#	ARTICLE	IF	CITATIONS
127	Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 857.	2.7	39
128	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- $\beta$ 1a in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101952.	2.1	0
129	Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 41-50.	3.6	29
130	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. <i>Multiple Sclerosis Journal</i> , 2019, 25, 856-866.	3.3	13
131	An update on the safety of treating relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 925-948.	2.5	15
132	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 845-856.	10.4	126
133	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. <i>Autoimmunity Reviews</i> , 2019, 18, 102365.	5.9	1
134	Examining the validity of the multiple-sclerosis walking scale-12 with Rasch analysis: Results from an Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101400.	2.1	9
135	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	2.5	21
136	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019, 266, 3098-3107.	3.8	1
137	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. <i>Journal of Neurological Sciences</i> , 2019, 405, 116423.	0.6	6
138	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. <i>Cells</i> , 2019, 8, 1114.	4.3	46
139	Newest Evidence for Tetrahydrocannabinol:Cannabidiol Oromucosal Spray From Postapproval Pragmatic Studies. <i>Neurodegenerative Disease Management</i> , 2019, 9, 3-7.	2.3	1
140	Pharmacoeconomics of synthetic therapies for multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1331-1340.	1.9	8
141	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. <i>European Journal of Neurology</i> , 2019, 26, e90-e91.	3.6	7
142	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. <i>Autoimmunity Reviews</i> , 2019, 18, 665-672.	5.9	29
143	Ageing with multiple sclerosis: prevalence and profile of cognitive impairment. <i>Neurological Sciences</i> , 2019, 40, 1651-1657.	2.0	45
144	Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. <i>Frontiers in Neurology</i> , 2019, 10, 337.	2.5	26

#	ARTICLE	IF	CITATIONS
145	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. <i>Neurological Sciences</i> , 2019, 40, 1383-1391.	2.0	12
146	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 2114-2124.	30.1	428
147	Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2022.	2.5	17
148	Management of dysphagia in multiple sclerosis: current best practice. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 47-54.	3.0	20
149	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019, 40, 155-165.	2.0	69
150	Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 324-326.	2.1	35
151	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. <i>Journal of Neurology</i> , 2019, 266, 411-416.	3.8	21
152	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 591-600.	3.3	13
153	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407.	3.3	41
154	Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates. <i>Journal of Psychiatry and Psychiatric Disorders</i> , 2019, 03, .	0.0	6
155	Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 531-536.	3.2	5
156	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2018, 90, e823-e831.	1.1	105
157	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. <i>Journal of Neurology</i> , 2018, 265, 828-835.	3.8	46
158	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 341-352.	3.4	1
159	Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 327-327.	6.0	3
160	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 167-174.	3.3	20
161	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 663-674.	3.3	39
162	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1234-1242.	3.3	36

#	ARTICLE	IF	CITATIONS
163	The Cost-effectiveness of Sativex®: The Italian Experience Based on " in Resistant Multiple Sclerosis Spasticity: Discontinuation Study in a Large Population of Italian Patients, SA.FE. Study". International Journal of Neurorehabilitation, 2018, 05, .	0.1	0
164	Authors'™ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®. Neurology and Therapy, 2018, 7, 391-393.	3.5	0
165	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	3.8	46
166	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	3.8	27
167	Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance Manager® evaluation study. Multiple Sclerosis and Related Disorders, 2018, 26, 46-51.	2.1	6
168	Cognitive assessment in multiple sclerosis"an Italian consensus. Neurological Sciences, 2018, 39, 1317-1324.	2.0	42
169	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	25
170	Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. European Journal of Neurology, 2018, 25, 1425-1431.	3.6	51
171	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. PLoS ONE, 2018, 13, e0200532.	2.5	9
172	Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated. Toxins, 2018, 10, 55.	3.5	30
173	Cognitive-motor dual-task interference: A systematic review of neural correlates. Neuroscience and Biobehavioral Reviews, 2017, 75, 348-360.	6.6	195
174	Multiple sclerosis and amyotrophic lateral sclerosis: a human leukocyte antigen challenge. Neurological Sciences, 2017, 38, 1501-1503.	2.0	5
175	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.8	37
176	Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opinion on Pharmacotherapy, 2017, 18, 45-55.	1.9	1
177	Computer-assisted cognitive rehabilitation on freezing of gait in Parkinson's™ disease: A pilot study. Neuroscience Letters, 2017, 654, 38-41.	2.1	16
178	Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. Journal of Neurology, 2017, 264, 494-502.	3.8	49
179	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	3.8	48
180	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	2.1	6

#	ARTICLE	IF	CITATIONS
181	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , 2017, 16, 976-986.	10.4	526
182	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon- $\beta$ 1a using RebiSmart <sup>®</sup> , the FUTURE study. <i>Neurological Sciences</i> , 2017, 38, 1999-2005.	2.0	16
183	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017, 38, 1849-1858.	2.0	30
184	A Comprehensive Review on Copemyl <sup>®</sup> . <i>Neurology and Therapy</i> , 2017, 6, 161-173.	3.5	7
185	Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 583-589.	2.2	11
186	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1258-1267.	3.3	230
187	Palliative care in progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 123-127.	2.8	5
188	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. <i>Frontiers in Psychology</i> , 2017, 8, 2216.	2.3	32
189	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). <i>PLoS ONE</i> , 2017, 12, e0180651.	2.5	28
190	Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. <i>Environmental Health</i> , 2017, 16, 91.	4.2	45
191	Offspring Number Does Not Influence Reaching the Disability <sup>™</sup> s Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 234.	4.2	18
192	A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1725.	4.2	28
193	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. <i>PLoS ONE</i> , 2016, 11, e0160261.	2.5	50
194	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 944-951.	6.0	95
195	Personalized therapy in multiple sclerosis: state of art and future perspectives. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 353-360.	0.6	2
196	Ataxia with vitamin E deficiency caused by a new compound heterozygous mutation. <i>Neurological Sciences</i> , 2016, 37, 1571-1572.	2.0	1
197	Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis". <i>J. Neuroimmunol.</i> 290 (2016 Jan. 15) 66-9]. <i>Journal of Neuroimmunology</i> , 2016, 295-296, 163.	2.4	0
198	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. <i>Quality of Life Research</i> , 2016, 25, 2755-2763.	3.2	10

#	ARTICLE	IF	CITATIONS
199	Hormone replacement in menopausal women with multiple sclerosis. <i>Neurology</i> , 2016, 87, 1430-1431.	1.1	3
200	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. <i>Drug Safety</i> , 2016, 39, 1163-1174.	3.2	39
201	Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods. <i>Neurological Sciences</i> , 2016, 37, 1931-1937.	2.0	13
202	When the word doesn't come out: A synthetic overview of dysarthria. <i>Journal of the Neurological Sciences</i> , 2016, 369, 354-360.	0.6	19
203	US health insurance is an obstacle to disease-modifying treatments in MS. <i>Neurology</i> , 2016, 87, 346-347.	1.1	7
204	Extensive bilateral striopallidodentate calcinosis: a 50-year history of hypoparathyroidism presenting like a parkinsonian syndrome. <i>Journal of Neurology</i> , 2016, 263, 1876-1879.	3.8	6
205	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	14
206	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. <i>European Journal of Neurology</i> , 2016, 23, 964-972.	3.6	34
207	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. <i>Journal of Neurology</i> , 2016, 263, 1802-1809.	3.8	18
208	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 366, 139-145.	0.6	28
209	Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	14
210	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735.	3.8	45
211	Expression of DNA methylation genes in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 290, 66-69.	2.4	17
212	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. <i>Neurological Sciences</i> , 2016, 37, 437-442.	2.0	7
213	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1741-1749.	3.3	33
214	Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. <i>Multiple Sclerosis Journal</i> , 2016, 22, 581-589.	3.3	24
215	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. <i>Neurological Sciences</i> , 2016, 37, 613-622.	2.0	16
216	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016, 23, 33-52.	1.5	44

#	ARTICLE	IF	CITATIONS
217	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS ONE, 2016, 11, e0153466.	2.5	32
218	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. PLoS ONE, 2016, 11, e0157721.	2.5	5
219	Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. Functional Neurology, 2016, 31, 21-3.	2.2	13
220	Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurology, 2015, 15, 252.	1.8	9
221	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	33
222	Italian Validation of the 12-Item Multiple Sclerosis Walking Scale. Multiple Sclerosis International, 2015, 2015, 1-6.	0.8	12
223	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics, 2015, 15, 251-268.	2.8	4
224	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184.	1.7	28
225	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1431-1442.	3.3	28
226	Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily. Journal of Neurology, 2015, 262, 923-930.	3.8	47
227	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics, 2015, 15, 803-824.	2.8	30
228	Multiple sclerosis: getting personal with induced pluripotent stem cells. Cell Death and Disease, 2015, 6, e1806-e1806.	6.4	18
229	Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 123-131.	3.3	120
230	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	8.0	78
231	Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. European Journal of Neurology, 2015, 22, 485-492.	3.6	20
232	Restless legs syndrome and multiple sclerosis: a population based case-control study in Catania, Sicily. European Journal of Neurology, 2015, 22, 1018-1021.	3.6	25
233	Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction. International Neurourology Journal, 2015, 19, 272-277.	1.3	13
234	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679.	2.5	71

#	ARTICLE	IF	CITATIONS
235	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 1029-1042.	2.8	56
236	Determinants of Sexual Impairment in Multiple Sclerosis in Male and Female Patients with Lower Urinary Tract Dysfunction: Results from an Italian Cross-Sectional Study. Journal of Sexual Medicine, 2014, 11, 2406-2413.	0.7	30
237	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	6.0	66
238	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Multiple Sclerosis Journal, 2014, 20, 220-226.	3.3	31
239	Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI. Multiple Sclerosis International, 2014, 2014, 1-9.	0.8	46
240	The Rao's Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. Neurological Sciences, 2014, 35, 79-82.	2.0	36
241	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	2.0	30
242	Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Acta Neurologica Scandinavica, 2014, 130, e41-e44.	2.2	5
243	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811.	3.3	11
244	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.1	229
245	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	2.7	46
246	Is the basic trunk control recovery different between stroke patients with right and left hemiparesis?. NeuroRehabilitation, 2014, 35, 215-220.	1.3	6
247	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.6	39
248	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	1.8	30
249	Interferon-beta-1a treatment has a positive effect on quality of life of relapsing/remitting multiple sclerosis: Results from a longitudinal study. Journal of the Neurological Sciences, 2014, 337, 180-185.	0.6	9
250	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.6	21
251	Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology, 2013, 261, 82-86.	2.4	46
252	Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS. BMC Neurology, 2013, 13, 97.	1.8	6

#	ARTICLE	IF	CITATIONS
253	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). <i>Journal of the Neurological Sciences</i> , 2013, 331, 94-97.	0.6	53
254	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013, 34, 1633-1637.	2.0	21
255	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1508-1517.	3.3	42
256	Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients. <i>Clinical Neuropharmacology</i> , 2013, 36, 114-116.	0.7	32
257	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 961-963.	3.3	17
258	Subcutaneous Interferon $\beta$ -1a May Protect against Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. <i>PLoS ONE</i> , 2013, 8, e74111.	2.5	53
259	Multiple Sclerosis in the Mount Etna Region: Possible Role of Volcanogenic Trace Elements. <i>PLoS ONE</i> , 2013, 8, e74259.	2.5	17
260	Aspetti che influenzano l'adesione alla terapia. , 2013, , 81-87.		0
261	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 329-334.	3.3	80
262	Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon $\beta$ -1a: results from the COGIMUS (COGNitive) Tj ETQq0 0 0 rgBTzOverlock 10 Tf 50		
263	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012, 12, 124.	1.8	84
264	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012, 12, 165.	1.8	81
265	Treatment of cognitive impairment in patients with multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1679-1699.	4.0	26
266	Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. <i>PLoS ONE</i> , 2012, 7, e41227.	2.5	25
267	Frequency and severity of headache is worsened by Interferon- $\beta$ therapy in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012, 125, 91-95.	2.2	40
268	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1355-1359.	6.0	31
269	The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2011, 18, 69-77.	3.6	304
270	Botulinum toxin improves dysphagia associated with multiple sclerosis. <i>European Journal of Neurology</i> , 2011, 18, 486-490.	3.6	50



#	ARTICLE	IF	CITATIONS
271	Clinical features of Sjogren's syndrome in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 109-114.	2.2	18
272	Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011, 32, 787-794.	2.0	33
273	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. <i>Neurological Sciences</i> , 2011, 32, 1223-1231.	2.0	44
274	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon $\beta$ -1a in the COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS (COGIMUS) study. <i>BMC Neurology</i> , 2011, 11, 125.	1.8	11
275	Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. <i>Multiple Sclerosis Journal</i> , 2011, 17, 273-280.	3.3	36
276	Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 220-222.	2.1	8
277	Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNITIVE) study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 145-150.	1.1	137
278	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011, 77, 145-150.	1.1	137
279	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 467-470.	2.0	43
280	Treatment options of cognitive impairment in multiple sclerosis. <i>Neurological Sciences</i> , 2010, 31, 265-269.	2.0	25
281	Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. <i>Patient Preference and Adherence</i> , 2010, 4, 1.	1.9	149
282	Cognitive and psychosocial features in childhood and juvenile MS. <i>Neurology</i> , 2010, 75, 1134-1140.	1.1	202
283	Lithium carbonate in amyotrophic lateral sclerosis. <i>Neurology</i> , 2010, 75, 619-625.	1.1	91
284	Pregnancy and fetal outcomes after interferon- $\beta$ exposure in multiple sclerosis. <i>Neurology</i> , 2010, 75, 1794-1802.	1.1	146
285	Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. <i>Journal of the Neurological Sciences</i> , 2010, 288, 96-100.	0.6	27
286	Quality of Life in Patients Affected by Multiple Sclerosis: A Systematic Review. , 2010, , 3769-3783.		1
287	Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. <i>Clinical Economics and Outcomes Research</i> , 2009, 1, 45.	1.9	2
288	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 620-626.	3.3	57

#	ARTICLE	IF	CITATIONS
289	Cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 2-8.	3.3	135
290	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€“remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 779-788.	3.3	178
291	Realâ€“life impact of early interferon $\beta$ therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009, 66, 513-520.	5.8	134
292	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009, 30, 193-199.	2.0	73
293	An exploration of anger phenomenology in multiple sclerosis. <i>European Journal of Neurology</i> , 2009, 16, 1312-1317.	3.6	16
294	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009, 286, 109-113.	0.6	23
295	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. <i>Clinical and Experimental Immunology</i> , 2009, 159, 159-168.	2.7	27
296	Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. <i>Journal of Neurology</i> , 2008, 255, 1250-1253.	3.8	74
297	Headache and Multiple Sclerosis: A Population-Based Case-Control Study in Catania, Sicily. <i>Cephalalgia</i> , 2008, 28, 1163-1169.	4.2	66
298	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 269, 49-53.	0.6	89
299	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008, 70, 1891-1897.	1.1	258
300	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 412-419.	3.3	78
301	Predictors of quality of life among patients with multiple sclerosis: An Italian cross-sectional study. <i>Journal of the Neurological Sciences</i> , 2007, 252, 121-129.	0.6	42
302	The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006, 12, 787-793.	3.3	352
303	Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 241-247.	2.2	29
304	Pharmacologic management of spasticity in multiple sclerosis. <i>Neurological Sciences</i> , 2006, 27, s310-s315.	2.0	5
305	Non-pharmacologic interventions for spasticity associated with multiple sclerosis. <i>Neurological Sciences</i> , 2006, 27, s316-s319.	2.0	3
306	Management of swallowing disorders in multiple sclerosis. <i>Neurological Sciences</i> , 2006, 27, s338-s340.	2.0	10

#	ARTICLE	IF	CITATIONS
307	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. <i>Journal of Neurology</i> , 2005, 252, 921-925.	3.8	20
308	The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsingâ€“remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2005, 252, 1255-1261.	3.8	30
309	Possible increasing risk of multiple sclerosis in Catania, Sicily. <i>Neurology</i> , 2005, 65, 1259-1263.	1.1	46
310	Brain atrophy and lesion load in a large population of patients with multiple sclerosis. <i>Neurology</i> , 2005, 65, 280-285.	1.1	143
311	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005, 11, 420-424.	3.3	102
312	Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. <i>Journal of Neurology</i> , 2004, 251, 1502-1506.	3.8	30
313	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004, 223, 69-71.	0.6	27
314	Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2003, 211, 55-62.	0.6	102
315	Prevalence and incidence of multiple sclerosis in Catania, Sicily. <i>Neurology</i> , 2001, 56, 62-66.	1.1	60
316	Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 404-407.	6.0	50
317	Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. <i>Multiple Sclerosis Journal</i> , 2001, 7, 101-104.	3.3	8
318	The Antiinflammatory Cytokine Interleukin-13 is not Detectable in the Circulation of Multiple Sclerosis Patients and is not Inducible by Interferon- $\gamma$ 1b Treatment, that Neither Modifies its ex vivo Secretion from Peripheral Blood Mononuclear Cells. <i>Autoimmunity</i> , 2000, 32, 265-270.	2.6	4
319	Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. <i>European Journal of Neurology</i> , 1998, 5, 283-286.	3.6	32
320	Blood levels of transforming growth factor-beta 1 (TGF- $\beta$ 1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN- $\beta$ 1b). <i>Clinical and Experimental Immunology</i> , 1998, 113, 96-99.	2.7	73
321	CIRCULATING SERUM LEVELS OF IL-1ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN- $\gamma$ TREATMENT. <i>Cytokine</i> , 1996, 8, 395-400.	3.2	81
322	Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1996, 70, 87-90.	2.4	112
323	Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. <i>Journal of Neurology</i> , 1996, 243, 293-301.	3.8	3
324	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. <i>SSRN Electronic Journal</i> , 0, , .	0.3	33

#	ARTICLE	IF	CITATIONS
325	Spasticity and Dystonia: A Brief Review. , 0, , .		0
326	An Internet- and Kinect-Based Multiple Sclerosis Fitness Intervention Training With Pilates Exercises: Development and Usability Study. JMIR Serious Games, 0, 11, e41371.	3.3	1
327	A dynamic interpretation of the FLIC index for the diagnosis of multiple sclerosis: a change of perspective. Journal of Neurology, 0, , .	3.8	1
328	Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 0, , jnnp-2023-333307.	6.0	0
329	Early reduction of retinal thickness predicts physical and cognitive disability in newly diagnosed multiple sclerosis patients: results from a cross-sectional study. Neurological Sciences, 0, , .	2.0	0
330	Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA). Journal of Neurology, 0, , .	3.8	0
331	Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. Multiple Sclerosis Journal, 0, , .	3.3	0